Everest Medicines Revenue and Competitors

Location

$310M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Everest Medicines's estimated annual revenue is currently $40.5M per year.(i)
  • Everest Medicines's estimated revenue per employee is $251,250
  • Everest Medicines's total funding is $310M.

Employee Data

  • Everest Medicines has 161 Employees.(i)
  • Everest Medicines grew their employee count by -23% last year.

Everest Medicines's People

NameTitleEmail/Phone
1
Chief Business OfficerReveal Email/Phone
2
Chief Scientific OfficerReveal Email/Phone
3
Chief Medical Officer, Internal MedicineReveal Email/Phone
4
Head BiometricsReveal Email/Phone
5
Senior Director, Search and EvaluationReveal Email/Phone
6
Senior Director, ImmunooncologyReveal Email/Phone
7
President and Chief Financial OfficerReveal Email/Phone
8
Chief Medical Officer, Infectious DiseaseReveal Email/Phone
9
Chief Technology OfficerReveal Email/Phone
10
Director Business DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.3M617%N/AN/A
#2
$354.3M461-2%$567.1MN/A
#3
$377.1M1876-1%N/AN/A
#4
$7.8M398%N/AN/A
#5
$5.4M270%N/AN/A
#6
$45M2246%N/AN/A
#7
$6.8M34-82%N/AN/A
#8
$9.2M4612%N/AN/A
#9
N/A69446%N/AN/A
#10
$15.5M775%N/AN/A
Add Company

What Is Everest Medicines?

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company's Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.

keywords:N/A

$310M

Total Funding

161

Number of Employees

$40.5M

Revenue (est)

-23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Everest Medicines News

2022-04-06 - Everest and CR Pharma sign MoU to launch company for ...

Everest Medicines has signed a memorandum of understanding (MoU) for a collaboration with China Resources Pharmaceutical Group (CR Pharma)...

2022-04-06 - Everest Medicines Announces that Topline Results from ...

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...

2022-03-30 - Everest Medicines Announces that Licensing Partner Pfizer ...

Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address...

2021-11-24 - Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index

SHANGHAI, Nov. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia, today announced that ...

2021-11-08 - Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia, today announced that i ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21.3M1614%N/A
#2
$44.3M1613%N/A
#3
$41.4M1615%N/A
#4
$23M161-2%N/A
#5
$15M16124%N/A